SEXUAL & REPRODUCTIVE RESEARCH / COMPARE
Two Peptides, Two Different Entry Points
One works on the endocrine axis that drives hormone production. The other works on the brain circuits that generate the experience of desire. Here is how they compare — and where they do not.
The short version
This page lines up kisspeptin and PT-141 on the dimensions that matter when reading research peptides: molecule class, primary mechanism, where each has been studied, how strong that evidence is, regulatory standing, and the single most important caution for each. The headline: these two operate at completely different levels of the reproductive and sexual system, they share no mechanism, and their evidence profiles could hardly be more different. Kisspeptin is a deeply characterized investigational endocrine signal with no approval. PT-141 (bremelanotide) is an FDA-approved brain-targeted peptide for one narrow indication. Neither is presented here with a human dose, and neither approval — or lack thereof — says anything about the safety or effectiveness of the other.
The comparison matrix
| Dimension | Kisspeptin | PT-141 (Bremelanotide) |
|---|---|---|
| Peptide class | KISS1-derived neuropeptide family (KP-10 to KP-54); KISS1R / GPR54 agonist | Synthetic cyclic heptapeptide lactam; melanocortin MC4R / MC3R agonist |
| Most-studied in | Hypothalamic amenorrhea, IVF triggering, LH stimulation in men and women, puberty biology | HSDD in premenopausal women; central sexual desire neuroscience |
| Evidence base (model) | Phase 1/2 human trials; mouse mechanistic work [1][3][7] | Two Phase 3 RCTs (n=1267); fMRI mechanistic study [9][10] |
| Administration studied | IV infusion, subcutaneous, intranasal (2025) [1][4][5] | Subcutaneous autoinjector (approved); IP in animal models [8] |
| Regulatory status | No approved product anywhere; fully investigational [2] | FDA-approved (NDA 210557, 2019) for HSDD in premenopausal women only [12] |
| Key caution | Tachyphylaxis: receptor desensitization with frequent use limits sustained dosing [4] | Approved indication is narrow; nausea ~40% long-term; BP elevation warning [11][12] |
Peptide class
The two molecules are structurally unrelated. Kisspeptin is a family of endogenous linear peptides encoded by the KISS1 gene — ranging from 10 to 54 amino acids, all sharing a C-terminal RF-amide motif that binds KISS1R (GPR54). They are natural signaling molecules that the hypothalamus already uses [7]. PT-141 is a synthetic cyclic heptapeptide — seven amino acids with a lactam bridge locking the ring — derived from alpha-MSH and designed specifically to activate central melanocortin receptors. It has no natural endogenous counterpart in the KISS1 family [12].
Most-studied in
Kisspeptin's published research covers the reproductive endocrine axis: LH pulsatility, hypothalamic amenorrhea, IVF oocyte triggering, male testosterone stimulation, puberty regulation, and fertility [1][3][4][5]. Its model is hormonal physiology. PT-141's research covers the neuroscience of sexual desire: brain processing of erotic stimuli, subjective desire ratings, and desire-related distress in women with HSDD [9][10]. Its model is motivational neuroscience. The two peptides answer different biological questions and their literatures rarely overlap.
Evidence base (model)
PT-141 has the stronger clinical evidence base. Two identical Phase 3 RCTs in over 1,200 women, a 52-week safety extension, and a rigorous fMRI mechanistic study underpin its approval [9][10][11]. That evidence is narrow — one indication, one population, one dose — but it is robustly conducted.
Kisspeptin's evidence is Phase 1 and Phase 2, carefully conducted, but in smaller cohorts and without placebo-controlled efficacy trials for any approved indication. The 2025 systematic review identified 29 interventional trials; no Phase 3 program or NDA submission exists [2]. Its strongest individual signal — the OHSS-free IVF trigger in 60 women — is compelling for that application [3], but the compound remains investigational across the board.
Administration studied
Kisspeptin has been studied by multiple routes as the field seeks a practical delivery form: intravenous infusion in hypothalamic amenorrhea studies [4], subcutaneous injection in the IVF Phase 2 trial [3], IV bolus in male LH studies [5], and most recently intranasal in the 2025 pilot that demonstrated effective LH stimulation without injection [1]. Subcutaneous PT-141/bremelanotide is the approved and most-studied human route [12]; animal mechanistic work uses intraperitoneal dosing [8].
Regulatory / WADA status
Kisspeptin has no approved product in any jurisdiction for any indication [2]. All human use is investigational and under medical supervision. Kisspeptin is not specifically named on the current WADA Prohibited List, but peptide hormones and hormone/metabolic modulators are regulated categories; athletes should consult their anti-doping authority before any use.
PT-141 (as bremelanotide) is FDA-approved for one specific indication: acquired, generalized HSDD in premenopausal women [12]. That approval does not extend to men, postmenopausal women, or performance enhancement in any population. Melanocortin receptor agonists without current regulatory approval for a relevant human therapeutic use fall under WADA's non-approved-substances framework (S0); athletes should consult current guidance.
Key caution
For kisspeptin, the defining caution is tachyphylaxis: the receptor desensitizes with frequent or continuous use, and the LH response measured in research attenuates within days. This is not a theoretical concern — it appears in multiple controlled studies and is consistent across routes [4]. It means the investigational dosing question is not just how much, but how often, and pushing frequency may defeat the purpose.
For PT-141, the defining caution is the gap between the approved indication and its reputation. The approval is real and meaningful for premenopausal women with clinically diagnosed HSDD. It is not an approval for anyone else, for any other purpose, or for material sold outside the pharmaceutical supply chain. Nausea at ~40% long-term and a blood-pressure warning are meaningful safety considerations even within the approved use [11][12]. Reading the two together, the lesson is consistent: mechanistically characterized signals, evidence bases that are real but bounded, and genuine limits that matter.